An open-label phase II study of the safety and efficacy of perifosine [KRX-0401; Keryx Pharmaceuticals] alone and in combination with dexamethasone for patients with relapsed or relapsed/refractory multiple myeloma.

Trial Profile

An open-label phase II study of the safety and efficacy of perifosine [KRX-0401; Keryx Pharmaceuticals] alone and in combination with dexamethasone for patients with relapsed or relapsed/refractory multiple myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Perifosine (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 08 Jun 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 04 Apr 2008 The estimated study completion date for this trial is now 1 Dec 2009, and the final data collection date for the primary outcome measure is July 2008, according to ClinicalTrials.gov.
    • 11 Dec 2007 Results presented at ASH 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top